Class Action Lawsuit Filed Against Applied Therapeutics, Inc. by The Schall Law Firm
On January 28, 2025, The Schall Law Firm, a renowned national shareholder rights litigation firm, announced a class action lawsuit against Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) (NASDAQ: APLT). The lawsuit alleges that the Company violated §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Class Period and Eligibility
The class action lawsuit covers securities purchased by investors during the period from January 3, 2024, to December 2, 2024, inclusive (the “Class Period”). Eligible investors who bought Applied Therapeutics’ securities during this timeframe are encouraged to contact The Schall Law Firm before February 18, 2025.
Allegations and Concerns
The lawsuit asserts that Applied Therapeutics made false and misleading statements regarding its business, operational, and financial results. Specifically, the Company reported positive clinical trial data for its lead product candidate, which allegedly misrepresented the actual progress and potential success of the trial. As a result of these alleged misrepresentations, Applied Therapeutics’ stock price was artificially inflated.
Impact on Investors
The class action lawsuit may have significant consequences for investors who purchased Applied Therapeutics’ securities during the Class Period. If the allegations are proven, investors may be entitled to compensation for their losses. The exact amount of damages will depend on the outcome of the case and the number of eligible claimants.
Impact on the World
The class action lawsuit against Applied Therapeutics could set a precedent for future securities fraud cases. It underscores the importance of transparency and truthfulness in corporate communications, particularly in the realm of clinical trial data reporting. The outcome of the case may also have broader implications for the biotech industry and investor confidence in clinical trial results.
Conclusion
Investors who purchased Applied Therapeutics securities during the Class Period are encouraged to contact The Schall Law Firm to discuss their potential eligibility to recover their losses. The lawsuit alleges that the Company made false and misleading statements regarding its business, operational, and financial results, leading to artificially inflated stock prices. The case could have significant consequences for investors and may set a precedent for future securities fraud cases. Stay tuned for updates on this developing story.
- Class action lawsuit filed against Applied Therapeutics, Inc.
- Allegations of securities fraud and violations of the Securities Exchange Act of 1934.
- Class Period: January 3, 2024, to December 2, 2024.
- Eligible investors encouraged to contact The Schall Law Firm before February 18, 2025.
- Potential consequences for investors and broader implications for the biotech industry.
